Linerixibat

Overview

Linerixibat is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL2387408).

Patent & exclusivity (US)

Per the FDA Orange Book (1 approved US product), the latest listed US patent on Linerixibat expires 6 Sept 2031 and exclusivity 17 Mar 2033. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

3-[[(3R,5R)-3-butyl-3-ethyl-7-methoxy-1,1-dioxo-5-phenyl-4,5-dihydro-2H-1lambda6,4-benzothiazepin-8-yl]methylamino]pentanedioic acid

Canonical SMILES

CCCC[C@@]1(CS(=O)(=O)C2=C(C=C(C(=C2)CNC(CC(=O)O)CC(=O)O)OC)[C@H](N1)C3=CC=CC=C3)CC

InChIKey

CZGVOBIGEBDYTP-VSGBNLITSA-N